Germany backed away from a planned variable discount pricing scheme for branded pharmaceuticals after industry opposition, opting instead for a fixed approach, according to Reuters. The original plan was designed to cut drug spending through increased markdowns to insurers on list prices. The change follows warnings from major manufacturers—including Eli Lilly and Boehringer Ingelheim—that the proposal could reduce investment in Germany.